AI-Driven Management of Type 2 Diabetes in China: Opportunities and Challenges

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Date 2025 Jan 13

PMID 39802619

Authors

Zhifang He

Wenyu Li

Affiliations

Soon will be listed here.

Abstract

With the aging of China's population and lifestyle changes, the number of patients with type 2 diabetes (T2D) has surged, posing a significant challenge to the public health system. This study explores the application and effectiveness of artificial intelligence (AI) technology in T2D management from a Chinese perspective. AI demonstrates substantial potential in personalized treatment planning, real-time monitoring and early warning, telemedicine, and health management. It not only enhances the precision and convenience of treatment but also aids in preventing and managing complications. Despite challenges in data privacy, technology popularization, standardization, and regulation, AI technology's continuous maturation and expanded application suggest its increasingly pivotal role in T2D management. In the future, through interdepartmental collaboration, policy support, and cultural adaptation, AI is poised to bring revolutionary changes to diabetes management in China and globally.

References

Motwani A, Shukla P, Pawar M . Ubiquitous and smart healthcare monitoring frameworks based on machine learning: A comprehensive review. Artif Intell Med. 2022; 134:102431. PMC: 9595483. DOI: 10.1016/j.artmed.2022.102431. View

Phillip M, Nimri R, Bergenstal R, Barnard-Kelly K, Danne T, Hovorka R . Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocr Rev. 2022; 44(2):254-280. PMC: 9985411. DOI: 10.1210/endrev/bnac022. View

Luo Z, Fabre G, Rodwin V . Meeting the Challenge of Diabetes in China. Int J Health Policy Manag. 2020; 9(2):47-52. PMC: 7054646. DOI: 10.15171/ijhpm.2019.80. View

Vettoretti M, Cappon G, Facchinetti A, Sparacino G . Advanced Diabetes Management Using Artificial Intelligence and Continuous Glucose Monitoring Sensors. Sensors (Basel). 2020; 20(14). PMC: 7412387. DOI: 10.3390/s20143870. View

Sun H, Zhang K, Lan W, Gu Q, Jiang G, Yang X . An AI Dietitian for Type 2 Diabetes Mellitus Management Based on Large Language and Image Recognition Models: Preclinical Concept Validation Study. J Med Internet Res. 2023; 25:e51300. PMC: 10667983. DOI: 10.2196/51300. View

Zhao Y, Yue R . Aging adipose tissue, insulin resistance, and type 2 diabetes. Biogerontology. 2023; 25(1):53-69. DOI: 10.1007/s10522-023-10067-6. View

Cobelli C, Renard E, Kovatchev B . The artificial pancreas: a digital-age treatment for diabetes. Lancet Diabetes Endocrinol. 2014; 2(9):679-81. PMC: 9888593. DOI: 10.1016/S2213-8587(14)70126-3. View

Li B, Li J, Jiang Y, Lan X . Experience and reflection from China's Xiangya medical big data project. J Biomed Inform. 2019; 93:103149. DOI: 10.1016/j.jbi.2019.103149. View

Khodve G, Banerjee S . Artificial Intelligence in Efficient Diabetes Care. Curr Diabetes Rev. 2022; 19(9):e050922208561. DOI: 10.2174/1573399819666220905163940. View

10.

Andres E, Meyer L, Zulfiqar A, Hajjam M, Talha S, Bahougne T . Telemonitoring in diabetes: evolution of concepts and technologies, with a focus on results of the more recent studies. J Med Life. 2019; 12(3):203-214. PMC: 6814890. DOI: 10.25122/jml-2019-0006. View

11.

Tseng T, Su C, Lai F . Fast Healthcare Interoperability Resources for Inpatient Deterioration Detection With Time-Series Vital Signs: Design and Implementation Study. JMIR Med Inform. 2022; 10(10):e42429. PMC: 9614630. DOI: 10.2196/42429. View

12.

Ma C, Luo Y, Zhang T, Hao Y, Xie X, Liu X . Predicting coronary heart disease in Chinese diabetics using machine learning. Comput Biol Med. 2024; 169:107952. DOI: 10.1016/j.compbiomed.2024.107952. View

13.

Yin Z, Song Y, Zhang J, Dai Q, Zhang X, Yang X . AI-Based Hematological Age Predictors and the Association Between Biological Age Acceleration and Type 2 Diabetes Mellitus - Chongqing Municipality, China, 2015-2021. China CDC Wkly. 2024; 6(45):1188-1193. PMC: 11561367. DOI: 10.46234/ccdcw2024.240. View

14.

Chen X, Giles J, Yao Y, Yip W, Meng Q, Berkman L . The path to healthy ageing in China: a Peking University-Lancet Commission. Lancet. 2022; 400(10367):1967-2006. PMC: 9801271. DOI: 10.1016/S0140-6736(22)01546-X. View

15.

Fagherazzi G, Ravaud P . Digital diabetes: Perspectives for diabetes prevention, management and research. Diabetes Metab. 2018; 45(4):322-329. DOI: 10.1016/j.diabet.2018.08.012. View

16.

Denes-Fazakas L, Simon B, Hartveg A, Kovacs L, Dulf E, Szilagyi L . Physical Activity Detection for Diabetes Mellitus Patients Using Recurrent Neural Networks. Sensors (Basel). 2024; 24(8). PMC: 11054023. DOI: 10.3390/s24082412. View

17.

Siddiqui S, Zhang Y, Lloret J, Song H, Obradovic Z . Pain-Free Blood Glucose Monitoring Using Wearable Sensors: Recent Advancements and Future Prospects. IEEE Rev Biomed Eng. 2018; 11:21-35. DOI: 10.1109/RBME.2018.2822301. View

18.

Margolis R, Derr L, Dunn M, Huerta M, Larkin J, Sheehan J . The National Institutes of Health's Big Data to Knowledge (BD2K) initiative: capitalizing on biomedical big data. J Am Med Inform Assoc. 2014; 21(6):957-8. PMC: 4215061. DOI: 10.1136/amiajnl-2014-002974. View

19.

Hu C, Jia W . Diabetes in China: Epidemiology and Genetic Risk Factors and Their Clinical Utility in Personalized Medication. Diabetes. 2017; 67(1):3-11. DOI: 10.2337/dbi17-0013. View

20.

Mader J . Personal Experiences With Coronavirus Disease 2019 and Diabetes: The Time for Telemedicine is Now. J Diabetes Sci Technol. 2020; 14(4):752-753. PMC: 7673167. DOI: 10.1177/1932296820930289. View